Comparison of Survival Rate in Primary Non-Small-Cell Lung Cancer Among Elderly Patients Treated With Radiofrequency Ablation, Surgery, or Chemotherapy

Journal Article · Sun Apr 15 04:00:00 EDT 2012 · Cardiovascular and Interventional Radiology

DOI:https://doi.org/10.1007/S00270-011-0194-Y· OSTI ID:21608557

Lee, Heon ^[1]; Han, Young Min; Chung, Gyung Ho ^[2]; Lee, Yong Chul ^[3]; Kwon, Keun Sang ^[4]; Lynch, David ^[5]

---

1. Seoul Medical Center, Department of Radiology (Korea, Republic of)
2. Chonbuk National University Medical School, Department of Radiology, Research Institute of Clinical Medicine (Korea, Republic of)
3. Chonbuk National University Medical School, Department of Internal Medicine, Research Institute of Clinical Medicine (Korea, Republic of)
4. Chonbuk National University Medical School, Department of Preventive Medicine, Research Institute of Clinical Medicine (Korea, Republic of)
5. National Jewish Health, Interstitial and Autoimmune Lung Disease Program, Department of Radiology (United States)

Purpose: We retrospectively compared the survival rate in patients with non-small-cell lung cancer (NSCLC) treated with radiofrequency ablation (RFA), surgery, or chemotherapy according to lung cancer staging. Materials and Methods: From 2000 to 2004, 77 NSCLC patients, all of whom had WHO performance status 0-2 and were >60 years old, were enrolled in a cancer registry and retrospectively evaluated. RFA was performed on patients who had medical contraindications to surgery/unsuitability for surgery, such as advanced lung cancer or refusal of surgery. In the RFA group, 40 patients with inoperable NSCLC underwent RFA under computed tomography (CT) guidance. These included 16 patients with stage I to II cancer and 24 patients with stage III to IV cancer who underwent RFA in an adjuvant setting. In the comparison group (n = 37), 13 patients with stage I to II cancer underwent surgery; 18 patients with stage III to IV cancer underwent chemotherapy; and 6 patients with stage III to IV cancer were not actively treated. The survival curves for RFA, surgery, and chemotherapy in these patients were calculated using Kaplan-Meier method. Results: Median survival times for patients treated with (1) surgery alone and (2) RFA alone for stage I to II lung cancer were 33.8 and 28.2 months, respectively (P = 0.426). Median survival times for patients treated with (1) chemotherapy alone and (2) RFA with chemotherapy for stage III to IV cancer were 29 and 42 months, respectively (P = 0.03). Conclusion: RFA can be used as an alternative treatment to surgery for older NSCLC patients with stage I to II inoperable cancer and can play a role as adjuvant therapy with chemotherapy for patients with stage III to IV lung cancer.

• OSTI ID: 21608557
• Journal Information: Cardiovascular and Interventional Radiology, Journal Name: Cardiovascular and Interventional Radiology Journal Issue: 2 Vol. 35; ISSN 0174-1551; ISSN CAIRDG
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
ABLATION
BODY
CHEMOTHERAPY
COMPUTERIZED TOMOGRAPHY
DIAGNOSTIC TECHNIQUES
DISEASES
LUNGS
MATERIALS
MEDICINE
NEOPLASMS
ORGANS
PATIENTS
RESPIRATORY SYSTEM
SURGERY
SURVIVAL CURVES
THERAPY
TOMOGRAPHY